Thrombogenicity is not reduced when heparin and phospholipid bonded circuits are used in a rabbit model of extracorporeal circulation

ASAIO Journal

Volumn 49, Issue 4, 2003, Pages 395-400

  Meinhardt, Jürgen P ^a   Annich, Gail M ^b   Miskulin, Judiann ^b   Kawai, Toshinori ^b   Ashton, Brian A ^b   Bartlett, Robert H ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADHESION; BLOOD; DOSIMETRY;

EXTRACORPOREAL CIRCUITS;

PHOSPHOLIPIDS;

FIBRINOGEN; HEPARIN; INDIUM 111; PHOSPHOLIPID;

ANIMAL EXPERIMENT; ARTICLE; BLOOD FLOW; CELL LABELING; CONTROLLED STUDY; EXPERIMENTAL MODEL; EXTRACORPOREAL CIRCULATION; FIBRINOGEN BLOOD LEVEL; HEPARINIZATION; INTRAVENOUS CATHETER; ISOTOPE LABELING; MATERIAL COATING; NONHUMAN; THROMBOCYTE; THROMBOCYTE ADHESION; THROMBOCYTE COUNT; THROMBOGENICITY; VASCULAR ENDOTHELIUM;

ANIMALS; BIOCOMPATIBLE MATERIALS; EXTRACORPOREAL CIRCULATION; FIBRINOGEN; HEPARIN; MATERIALS TESTING; PHOSPHOLIPIDS; PLATELET ADHESIVENESS; PLATELET COUNT; POLYVINYL CHLORIDE; RABBITS; SURFACE PROPERTIES; THROMBOSIS;

EID: 0041807798     PISSN: 10582916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Bartlett RH: Extracorporeal life support for cardiopulmonary failure. Curr Probl Surg 27: 621-705, 1990.
2. Zwischenberger JB, Bartlett RH: ECMO - Extracorporeal cardiopulmonary support in critical care. Ann Arbor, MI: Extracorporeal Life Support Organization, 1995.
3. Bücherl ES: Künstliche organe (Artificial organs), Darmstadt: Wissenschaftliche Buchgesellschaft, 1994.
4. van Oeveren W, Wildevuur CRH: Blood compatibility of cardiopulmonary bypass circuits. Perfusion 2: 237-244, 1987.
5. Gallimore MJ, Heller W, Fuhrer G, Wendel HP, Klaffschenkel R, Hoffmeister HE: Contact activation, heparins and cardiopulmonary bypass. Thromb Haemost 68: 91-92, 1992.
6. Whittlesey GC, Kundu SK, Salley SO, Nowlen TT, Klein MD: Is heparin necessary for extracorporeal circulation? Trans Am Soc Artif Intern Organs 34: 823-826, 1988.
7. Thakur ML, Welch MJ, Joist JH, Coleman RE: Indium-111-labeled platelets: Studies on preparation and evaluation of in vitro and in vivo functions. Thromb Res 9: 345-357, 1976.
8. Ardlie NG, Packham MA, Mustard JF: Adenosine diphosphate-induced platelet aggregation in suspensions of washed rabbit platelets. Br J Haematol 19: 7-17, 1970.
9. 111In-labeled platelets to measure survival of least dense and most dense platelets concurrently. Blood 61: 362-367, 1983.
10. Larm O, Larsson R, Olsson P: A new non-thrombogenic surface prepared by selective covalent binding of heparin via a modified reducing terminal residue. Biomater Med Devices Artif Organs 11: 161-173, 1983.
11. Bindslev L, Eklund J, Norlander O, et al: Treatment of acute respiratory failure by extracorporeal carbon dioxide elimination performed with a surface heparinized artificial lung. Anesthesiology 67: 117-120, 1987.
12. Edmunds LH: Breaking the blood-biomaterial barrier. ASAIO J 41: 824-830, 1995.
13. Salzman EW, Rosenberg RD, Smith MH, Lindon JN, Favreau L: Effect of heparin and heparin fractions on platelet aggregation. J Clin Invest 65: 64-73, 1980.
14. Gemmell C, Ramirez S, Yeo E, Sefton M: Platelet activation in whole blood by artificial surfaces: Identification of platelet-derived microparticles and activated platelet binding to leukocytes as material-induced activation events. Journal of Laboratory & Clinical Medicine 125: 276-287, 1995.
15. LaBarre D: Heparin-like polymer surfaces: Control of coagulation and complement activation by insoluble functionalized polymer. International Journal of Artificial Organs 13: 651-657, 1990.